{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:35:43Z","timestamp":1792467343885,"version":"4.5.0"},"reference-count":31,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2016,6,5]],"date-time":"2016-06-05T00:00:00Z","timestamp":1465084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2016,8]]},"abstract":"Abstract<\/jats:title>\n \n Hypercalcemia of malignancy (\n HCM<\/jats:styled-content>\n ) is a serious metabolic complication whose population\u2010based prevalence has not been quantified. Rates of\n HCM<\/jats:styled-content>\n differ by tumor type, with highest rates reported in multiple myeloma and lowest among colorectal and prostate cancer patients. This analysis estimates\n HCM<\/jats:styled-content>\n prevalence in the\n US<\/jats:styled-content>\n . This retrospective study used the Oncology Services Comprehensive Electronic Records (\n OSCER<\/jats:styled-content>\n ) warehouse of electronic health records (\n EHR<\/jats:styled-content>\n ) including laboratory values from 569000 patients treated at 565 oncology outpatient sites.\n OSCER<\/jats:styled-content>\n data were projected to the national level by linking\n EHR<\/jats:styled-content>\n to claims data. Cancer patients included were \u226518\u00a0years, and had serum calcium (Ca) and albumin (for corrected serum Ca [\n CSC<\/jats:styled-content>\n ]) records. Period prevalence was estimated by\n HCM CTCAE<\/jats:styled-content>\n grade, tumor type, and year (2009\u20132013). Estimates were adjusted to capture patients diagnosed with\n HCM<\/jats:styled-content>\n outside oncology practices based on a subset of patients linkable to office and hospital data. The analysis included 68023 (2009) to 121482 (2013) cancer patients. In 2013, patients with\n HCM<\/jats:styled-content>\n had a median of six Ca tests, 69.7% had chemotherapy, and 34% received bone modifying agents.\n HCM<\/jats:styled-content>\n rates were highest for multiple myeloma patients (7.5% [2012]\u201310.2% [2010]), lowest for prostate cancer (1.4% [2012]\u20132.1% [2011]).The estimated adjusted annual prevalence of\n HCM<\/jats:styled-content>\n from 2009 to 2013 was 95441, 96281, 89797, 70158, and 71744, respectively.\n HCM<\/jats:styled-content>\n affected 2.0\u20132.8% of all cancer patients.\n EHR<\/jats:styled-content>\n data from oncology clinics were critical for this study because these data contain results from laboratory studies (i.e., serum calcium values) that are routinely ordered in that setting. We estimated that the prevalence of\n HCM<\/jats:styled-content>\n in the\n US<\/jats:styled-content>\n in 2013 is 71744, affecting approximately 2% of cancer patients overall. This percentage differs by tumor type and appears to have decreased over the five\u2010year study period.\n <\/jats:p>","DOI":"10.1002\/cam4.749","type":"journal-article","created":{"date-parts":[[2016,6,5]],"date-time":"2016-06-05T21:58:40Z","timestamp":1465163920000},"page":"2091-2100","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["Prevalence of hypercalcemia among cancer patients in the United States"],"prefix":"10.1002","volume":"5","author":[{"given":"Victor M.","family":"Gastanaga","sequence":"first","affiliation":[{"name":"Amgen Inc. Thousand Oaks and South San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee S.","family":"Schwartzberg","sequence":"additional","affiliation":[{"name":"The West Clinic Memphis Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajul K.","family":"Jain","sequence":"additional","affiliation":[{"name":"Kite Pharma Inc. Santa Monica California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Pirolli","sequence":"additional","affiliation":[{"name":"IMS Health Plymouth Meeting Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Quach","sequence":"additional","affiliation":[{"name":"PRA Health Sciences Blue Bell Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane M.","family":"Quigley","sequence":"additional","affiliation":[{"name":"PRA Health Sciences Blue Bell Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Mu","sequence":"additional","affiliation":[{"name":"Glaxo Smith Kline Collegeville Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Scott Stryker","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks and South San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Liede","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks and South San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,6,5]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02470312"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026597816193"},{"key":"e_1_2_8_4_1","first-page":"51","article-title":"Hypercalcemia of Malignancy. Epidemiology and Pathogenesis. Clinical Reviews in Bone and Mineral","volume":"1","author":"Martin T. J.","year":"2000","journal-title":"Metabolism"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1683-5"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnephrol.2003.08.015"},{"key":"e_1_2_8_7_1","first-page":"635","article-title":"Hypercalcemia in Malignancy","volume":"153","author":"Strewler G. J.","year":"1990","journal-title":"West J. Med."},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986711796642490"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.moo.0000193176.54450.c4"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2004.04.1486"},{"key":"e_1_2_8_11_1","first-page":"1551","article-title":"Cancer\u2010induced Hypercalcemia","volume":"29","author":"Lumachi F.","year":"2009","journal-title":"Anticancer Res."},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mph.0000151932.47598.00"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19841115)54:10<2132::AID-CNCR2820541013>3.0.CO;2-V"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930701)72:1<256::AID-CNCR2820720145>3.0.CO;2-D"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt225"},{"key":"e_1_2_8_16_1","unstructured":"US Department of Health and Human Services.National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Published: May 28 2009 (version 4.03: June 14 2010)."},{"key":"e_1_2_8_17_1","first-page":"1395","volume-title":"Tietz Textbook of Clinical Chemistry","author":"Endres D. B.","year":"1999"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0885066613507530"},{"key":"e_1_2_8_19_1","volume-title":"Projection Methods Using Oncology Electronic Health Records to Produce Nationally Representative Estimates","author":"Quach D.","year":"2013"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.105"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.1845"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/amiajnl-2014-002974"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2012.000735"},{"key":"e_1_2_8_24_1","unstructured":"ASCO.2013.Press Release: ASCO Launches Formal Development of CancerLinQ\u2122 a Learning Health System to Transform Cancer Care and Improve Outcomes for Patients. Available athttp:\/\/www.asco.org\/press-center\/asco-launches-formal-development-cancerlinq%E2%84%A2-learning-health-system-transform-cancer(accessed 20 June 2014)."},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2124"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930215)71:4<1309::AID-CNCR2820710423>3.0.CO;2-M"},{"key":"e_1_2_8_27_1","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.annepidem.2014.06.015","article-title":"Validation of bone metastases coding in an oncology electronic medical records database and a commercial claims database","volume":"24","author":"Hernandez R. K.","year":"2014","journal-title":"Ann. Epidemiol."},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.304"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-7-499"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.71.831.28"},{"key":"e_1_2_8_31_1","volume-title":"Prevalence of Hypercalcemia of Malignancy in the United States","author":"Gastanaga V. M.","year":"2013"},{"key":"e_1_2_8_32_1","volume-title":"Prevalence of Hypercalcemia of Malignancy in the United States: projection Methods Using Oncology Electronic Health Records (EHR)","author":"Gastanaga V. M.","year":"2013"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.749","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.749","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.749","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T10:49:32Z","timestamp":1696589372000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,5]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1002\/cam4.749"],"URL":"https:\/\/doi.org\/10.1002\/cam4.749","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,5]]},"assertion":[{"value":"2015-10-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-03-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-06-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}